ArticleInternational journal of impotence research2024
Daily low-dose tadalafil may reduce the penile curvature progression rate in patients with acute Peyronie's disease: a retrospective comparative analysis.
Article in International journal of impotence research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Active Peyronie's disease as an early antifibrotic treatment window: a translational review.Sexual medicine · 2026Review
- Bridging fibrosis and function: an integrated mechanistic and therapeutic framework for Peyronie's disease and related erectile dysfunction.Sexual medicine · 2026Review
- Congenital Penile Curvature Is Associated With Larger Penile Dimensions: A Matched Case-Control Study.Andrology · 2026Article
- Combination therapy for acute Peyronie' s disease: a success story of translation from bench to bedside.Nature reviews. Urology · 2026Article
- From fibrosis to restoration: the multimodal 3 Ts protocol for Peyronie's disease.International journal of impotence research · 2026Review
- Current status of non-surgical treatments for Peyronie's disease.Translational andrology and urology · 2026Article
- Contemporary Management Strategies for Peyronie's Disease: A Comprehensive Review.Research and reports in urology · 2026Review
- Platelet-rich plasma intra-plaque injections rapidly reduce penile curvature and improve sexual function in Peyronie's disease patients: results from a prospective large-cohort study.World journal of urology · 2025Article
- Collagen fleece grafting for surgical treatment of patients with mild to severe peyronie's curvatures.International urology and nephrology · 2025Article
- Diagnosis and Management of Peyronie's Disease: A Clinical Consensus Statement and Recommendations from the Korean Society for Sexual Medicine and Andrology.The world journal of men's health · 2025Review
- Comparison of Current International Guidelines on Premature Ejaculation: 2024 Update.Diagnostics (Basel, Switzerland) · 2024Review
- Acute Phase Peyronie's Disease: Where Do We Stand?Cureus · 2024Review
- Is there a new role for oral therapy to treat peyronie's disease? Commentary on Daily low-dose tadalafil may reduce the penile curvature progression rate in patients with acute Peyronie's Disease: a retrospective comparative analysis.International journal of impotence research · 2024Article
- [Current treatment concepts for Peyronie's disease].Urologie (Heidelberg, Germany) · 2023Article
- Molecular Mechanisms and Risk Factors Related to the Pathogenesis of Peyronie's Disease.International journal of molecular sciences · 2023Review
- Voice Assistants as Consultants for Male Patients with Sexual Dysfunction: A Reliable Option?International journal of environmental research and public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to evaluate the clinical outcomes of patients in acute phase of Peyronie's disease (PD) treated with daily low-dose of Tadalafil. An observational retrospective study involving patients in acute phase of PD with erectile dysfunction (ED) was designed. All subjects were offered Tadalafil 5 mg one tablet a day. Men who accepted treatment were compared to patients who refused Tadalafil. Penile curvature progression was chosen as the primary outcome. PD Questionnaire (PDQ) and IIEF-5 scores were selected as secondary outcomes. A total of 191 patients were included in the study (108 intervention vs. 83 control). Penile curvature progression rate was significantly lower in subjects taking Tadalafil at 12 weeks (25.9% vs. 39.7%, p = 0.042). Mean IIEF-5 score improved in the intervention group, becoming significantly higher compared to the observation group at 12 weeks (19.3 vs. 11.2 points, p < 0.001). Mean PDQ-Overall and PDQ-Penile Pain scores only improved in the intervention group and the statistically significant differences at baseline between groups became not statistically significant at 12 weeks (p = 0.001 vs. p = 0.232 and p < 0.001 vs. p = 0.078, respectively). Daily low-dose Tadalafil in patients with acute phase of PD seems to significantly reduce the penile curvature progression rate compared to observation, especially when it is administrated early. It also appears to improve erectile function and PD-related symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.